Mesenchymal stem cell-based COVID-19 therapy: bioengineering perspectives

N Karakaş, S Üçüncüoğlu, D Uludağ, BS Karaoğlan… - Cells, 2022 - mdpi.com
The novel pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
causes coronavirus disease 2019 (COVID-19). Mesenchymal stem cells (MSCs) are …

Focusing on the cytokine storm in the battle against COVID-19: the rising role of mesenchymal-derived stem cells

A Naeem, A Waseem, AJ Siddiqui, B Ray, R Sinha… - Stem Cells, 2024 - Elsevier
A worldwide pandemic known as coronavirus disease-19 (COVID-19) has caused various
clinical complications, ranging from carriers without symptoms to acute respiratory distress …

[HTML][HTML] Female reproductive health in SARS-CoV-2 pandemic era

R Nateghi, S Ghashghaei, B Shokoohian… - … journal of fertility & …, 2021 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic struck global
health systems with over-growing demands in many fields of health care; yet, reproductive …

[PDF][PDF] Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report

D Primorac, S Stojanović Stipić, M Strbad… - Croatian medical …, 2021 - hrcak.srce.hr
We report on a case of severe COVID-19 in a 50-year-old male patient who was treated with
an infusion of parenteral mesenchymal stem cells (MSC)(Table 1). The pathophysiologic …

[HTML][HTML] Immune-based therapeutic approaches in COVID-19

A Moeinafshar, N Yazdanpanah, N Rezaei - Biomedicine & …, 2022 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family …

Wharton's jelly-mesenchymal stem cells treatment for severe COVID 19 patients: 1-year follow-up

M Saleh, AA Vaezi, AA Sohrabpour, M Barkhordar… - Gene Reports, 2022 - Elsevier
Background Recently, attention has been focused on mesenchymal stem cells (MSC)
because of their unique ability to suppress inflammation induced by cytokine storms caused …

[HTML][HTML] Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

XY Hou, LM Danzeng, YL Wu, QH Ma… - World Journal of Stem …, 2024 - ncbi.nlm.nih.gov
Abstract Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection …

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial …

E Gorman, M Shankar-Hari, P Hopkins, WS Tunnicliffe… - Trials, 2022 - Springer
Abstract Background Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to
immunomodulatory and reparative properties. This trial investigates a novel CD362 …

Mesenchymal stromal cells and pleiotropic therapeutic advantages in COVID-19 management

VK Singh, UKS Vaksh, P Sharma - Stem Cells, 2024 - Elsevier
The pandemic burst of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or
coronavirus disease 2019 (COVID-19) infections shattered existing medical and research …

Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope

D Pal, J Goyal, U Sharma, A Sharma, S Prashar… - Life Sciences, 2021 - Elsevier
COVID-19 is a serious viral infection that struck the world in December 2019 starting from
Wuhan in China, spreading subsequently to all over the world. The disease has baffled …